Difference between revisions of "Mutschler 2022 MitoFit"
Tindle Lisa (talk | contribs) |
|||
| Line 6: | Line 6: | ||
|year=2022-04-07 | |year=2022-04-07 | ||
|journal=MitoFit Prep | |journal=MitoFit Prep | ||
|abstract=Damaged or chemically altered membranes are highly likely to play a central role at the molecular level in many chronic and acute diseases as well as in aging. Damage is often related to inflammatory processes that release large amounts of radical oxygen species (ROS). For several years, membrane replacement has been investigated as a therapeutic option for various diseases. Furthermore, liposomes represent potentially valuable tools for this purpose to force the integration of membrane material into the body's own tissue. Unfortunately, however, this method has not yet arrived in practice. Therefore, we have made our own efforts to establish membrane replacement in our practice, including the therapeutic use of liposomal products of high quality. Here we report on two successfully treated cases. <br><br> | |abstract=[[Mutschler 2022 Abstract Bioblast]]: Damaged or chemically altered membranes are highly likely to play a central role at the molecular level in many chronic and acute diseases as well as in aging. Damage is often related to inflammatory processes that release large amounts of radical oxygen species (ROS). For several years, membrane replacement has been investigated as a therapeutic option for various diseases. Furthermore, liposomes represent potentially valuable tools for this purpose to force the integration of membrane material into the body's own tissue. Unfortunately, however, this method has not yet arrived in practice. Therefore, we have made our own efforts to establish membrane replacement in our practice, including the therapeutic use of liposomal products of high quality. Here we report on two successfully treated cases. <br><br> | ||
|keywords=membranes, liposomes, phospholipids, phosphatidylcholine, membrane replacement therapy, liposomal formulations, mitochondria, adducts, detoxification | |keywords=membranes, liposomes, phospholipids, phosphatidylcholine, membrane replacement therapy, liposomal formulations, mitochondria, adducts, detoxification | ||
|editor=Tindle-Solomon L | |editor=Tindle-Solomon L | ||
Revision as of 06:47, 31 May 2022
Mutschler 2022 MitoFit
| Mutschler R (2022) Membranes as therapeutic targets - liposomes as therapeutic options. MitoFit Preprints 2022.10. https://doi.org/10.26124/mitofit:2022-0010 |
»
Membranes as therapeutic targets - liposomes as therapeutic options
Mutschler Rainer (2022-04-07) MitoFit Prep
Abstract: Mutschler 2022 Abstract Bioblast: Damaged or chemically altered membranes are highly likely to play a central role at the molecular level in many chronic and acute diseases as well as in aging. Damage is often related to inflammatory processes that release large amounts of radical oxygen species (ROS). For several years, membrane replacement has been investigated as a therapeutic option for various diseases. Furthermore, liposomes represent potentially valuable tools for this purpose to force the integration of membrane material into the body's own tissue. Unfortunately, however, this method has not yet arrived in practice. Therefore, we have made our own efforts to establish membrane replacement in our practice, including the therapeutic use of liposomal products of high quality. Here we report on two successfully treated cases.
• Keywords: membranes, liposomes, phospholipids, phosphatidylcholine, membrane replacement therapy, liposomal formulations, mitochondria, adducts, detoxification
• Bioblast editor: Tindle-Solomon L
Labels: MiParea: Patients Pathology: Inherited, Parkinson's Stress:Oxidative stress;RONS Organism: Human
membranes, liposomes, lipids, Bioblast 2022
